Small molecule inhibitors of BRAF in clinical trials.

Article Details

Citation

Copy to clipboard

Zambon A, Niculescu-Duvaz I, Niculescu-Duvaz D, Marais R, Springer CJ

Small molecule inhibitors of BRAF in clinical trials.

Bioorg Med Chem Lett. 2012 Jan 15;22(2):789-92. doi: 10.1016/j.bmcl.2011.11.060. Epub 2011 Dec 3.

PubMed ID

22222036 [ View in PubMed

]

Abstract

Over the last few years, BRAF has emerged as a validated target in melanoma. This review summarises recent advances in the development of BRAF inhibitors, focussing on agents that have been assessed clinically.

DrugBank Data that Cites this Article

Binding Properties

Drug	Target	Property	Measurement	pH	Temperature (°C)
PLX-4720	Serine/threonine-protein kinase B-raf	IC 50 (nM)	13	N/A	N/A	Details
Regorafenib	Serine/threonine-protein kinase B-raf	IC 50 (nM)	28	N/A	N/A	Details